Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7439937 | 0.96 | KMT2A (0.50) | KMT2AMEN1PKMMAPTNPC1 | |
| SCHEMBL2421857 | 0.94 | KMT2A (0.52) | KMT2AMEN1PKMMAPTNPC1 | |
| SCHEMBL2422541 | 0.94 | KMT2A (0.56) | KMT2AMEN1PKMMAPTNPC1 | |
| SCHEMBL2425856 | 0.92 | KMT2A (0.54) | KMT2AMEN1PKMNPC1APOBEC3A | |
| SCHEMBL2420432 | 0.92 | KMT2A (0.53) | KMT2AMEN1PKMMAPTNPC1 | |
| SCHEMBL2423174 | 0.91 | KMT2A (0.59) | KMT2AMEN1PKMNPC1APOBEC3A | |
| SCHEMBL6431623 | 0.91 | KMT2A (0.55) | KMT2AMEN1PKMNPC1APOBEC3A | |
| SCHEMBL2427448 | 0.90 | KMT2A (0.52) | KMT2AMEN1PKMMAPTNPC1 | |
| SCHEMBL2427569 | 0.90 | KMT2A (0.52) | KMT2AMEN1PKMNPC1APOBEC3A | |
| SCHEMBL7438443 | 0.89 | KMT2A (0.48) | KMT2AMEN1PKMMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012995-B1 | Pharmaceutically active sulfonamide derivatives | MERCK SERONO SA (CH) | 2011-09-06 | — | — | US | claimed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | claimed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | claimed |
| EP-1218374-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2002-07-03 | — | — | EP | claimed |
| WO-2001023378-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-05 | — | — | WO | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8012995-B1 | Pharmaceutically active sulfonamide derivatives | MERCK SERONO SA (CH) | 2011-09-06 | — | — | US | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | LABORATOIRES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-2026802-A2 | JNK INHIBITORS FOR TREATMENT OF SKIN DISEASES | Laboratoires Serono SA (CH) | 2009-02-25 | — | — | EP | disclosed |
| EP-1904181-A2 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETREOSIS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | disclosed |
| WO-2007141224-A2 | JNK INHIBITORS FOR TREATMENT OF SKIN DISEASES | LABORATOIRES SERONO SA (CH) | 2007-12-13 | — | — | WO | disclosed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | disclosed |
| WO-2007011762-A2 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETREOSIS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | MAPKAPK2, JUN, MAP3K13 | KMT2A 2086/4885MEN1 4590/4885PKM 2126/4885 |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | KMT2A 2101/4885MEN1 3205/4885PKM 2329/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | KMT2A 3013/4885MEN1 1582/4885PKM 2710/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | KMT2A 847/4885MEN1 3898/4885PKM 1872/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | KMT2A 847/4885MEN1 3898/4885PKM 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.